Show 10 5 10 15 20 50 100 250 Sort by year (new to old) Actions News feed Embed this list Save this search Mark all Export Your filters: cql: author="SALLES, G" or (type exact bookEditor and editor="SALLES, G") Mark journalArticle A1 Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study A Chanan-Khan, P Cramer, F Demirkan, G Fraser, RS Silva, S Grosicki, A Pristupa, A Janssens, J Mayer, NL Bartlett, et al. (2016) LANCET ONCOLOGY. 17(2). p.200-211 Mark conference C3 Pattern of infections observed during the maintenance phase in the PRIMA study M Bouteloup, J Seymour, P Feugier, Fritz Offner (UGent) , A Lopez-Guillermo, R Bouabdallah, L Pedersen, P Brice, D Belada and G Salles (2011) ANNALS OF ONCOLOGY. 22(suppl. 4). p.189-189 Mark conference C3 Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study F Morschhauser, J Seymour, P Feugier, Fritz Offner (UGent) , A Lopez-Guillermo, R Bouabdallah, L Pedersen, P Brice, D Belada, L Xerri, et al. (2011) ANNALS OF ONCOLOGY. 22(suppl. 4). p.89-89 Mark conference C3 FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation H Ghesquieres, J Seymour, Fritz Offner (UGent) , P Feugier, P Brice, C Haioun, O Casasnovas, J Catalano, F Jardin, L Xerri, et al. (2011) ANNALS OF ONCOLOGY. 22(suppl. 4). p.187-188 Mark conference C3 Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study G Salles, J Catalano, P Feugier, Fritz Offner (UGent) , R Bouabdallah, D Caballero, P Brice, LM Pedersen, C Haioun, D Belada, et al. (2010) HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 95(suppl. 2). p.229-229 Mark journalArticle A1 Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study S CHOQUET, V LEBLOND, R HERBRECHT, G SOCIE, AM STOPPA, P VANDENBERGHE, A FISCHER, F MORSCHHAUSER, G SALLES, W FEREMANS, et al. (2006) BLOOD. 107(8). p.3053-3057 Mark conference C3 Efficacy and safety of Rituximab in B-cell post transplantation lymphoproliferative disorders (B-PTLD): Preliminary results of a multicenter, open label, phase II trial (M39037 TRIAL) S CHOQUET, R HERBRECHT, G SOCIE, AM STOPPA, P VANDENBERGHE, W FEREMENS, A FISCHER, F MORSCHAUSER, G SALLES, E VILMER, et al. (2002) BLOOD. 100(11).